BioSpace News Archive

Cogent Biosciences, Inc., a biotechnology company focused on developing precision therapies for genetically defined diseases, announced positive lead-in data from its ongoing Phase 3 PEAK trial evaluating the selective KIT D816V inhibitor bezuclastinib in patients with Gastrointestinal Stromal Tumors.

Replimune Group, Inc. announced updated data from the first 75 patients in the anti-PD1 failed melanoma cohort of the IGNYTE clinical trial along with data from the ongoing Phase 1 trial of RP2 combined with nivolumab in patients with uveal melanoma are being presented at the ASCO annual meeting.

Gracell Biotechnologies Inc. presented long-term follow-up data from a multicenter study evaluating GC012F, a B-cell maturation antigen and CD19 dual-targeted autologous CAR-T therapeutic candidate, in RRMM during an oral abstract presentation at the 2023 American Society of Clinical Oncology Annual Meeting.

The Janssen Pharmaceutical Companies of Johnson & Johnson announced the first-ever results from the Phase 1b RedirecTT-1 study of TECVAYLI®, a first-in-class BCMAxCD3 bispecific antibody, and talquetamab, a first-in-class GPRC5DxCD3 bispecific antibody, showing a high overall response rate among patients with relapsed or refractory multiple myeloma.

GRAIL, LLC, a healthcare company whose mission is to detect cancer early when it can be cured, announced data evaluating the Galleri® multi-cancer early detection test’s ability to detect a cancer signal and predict the cancer signal origin in asymptomatic individuals in the real-world setting.

GRAIL, LLC announced results from a retrospective analysis of the interventional PATHFINDER study to assess whether diagnostic evaluations of individuals who received a cancer signal detected result with the Galleri® multi-cancer early detection test were appropriately directed by the test’s cancer signal origin predictions.

The Janssen Pharmaceutical Companies of Johnson & Johnson announced updated results from the pivotal Phase 1/2 MonumenTAL-1 study of the investigational bispecific antibody talquetamab in the treatment of patients with relapsed or refractory multiple myeloma.

Sutro Biopharma, Inc. announced that results from a Phase 1 dose-expansion study of luveltamab tazevibulin, a novel Folate receptor alpha -targeting ADC, in patients with advanced ovarian cancer were featured in an oral presentation at the 2023 American Society of Clinical Oncology Annual Meeting in Chicago, IL.

Evaxion Biotech A/S, a clinical-stage biotechnology company specializing in the development of AI-powered immunotherapies, presented promising clinical data from its EVX-01 Phase 1 dose escalation trial in metastatic melanoma at the 2023 ASCO annual meeting in Chicago, Illinois.

Innovent Biologics, Inc. updated the Phase 1b efficacy and safety results of IBI939 combined with sintilimab in previously untreated PD-L1-selected NSCLC without sensitizing mutations at the 2023 American Society of Clinical Oncology Annual Meeting.